DosePro™- the world’s first & only single use, easy to use, disposable, needle free injection system that removes the anxiety associated with a fear of needles Zogenix is a showcase example of a Specialty Phama Co with a foundation in Drug Delivery. Since inception in late 2006, Zogenix has raised $170MM in private capital, acquired and developed a unique drug delivery technology in combination with a drug product through full clinical development, NDA approval and U.S. launch. Zogenix drug delivery technology is called – DosePro™- the world’s first & only single use, easy to use, disposable, needle free injection system that removes the anxiety associated with a fear of needles. Zogenix made history in July 2009 when the U.S. FDA-approved the company’s NDA for the very first product ever that utilizes a pre-filled needle-free injection technology for the treatment of migraine and cluster headaches; SUMAVEL DosePro (sumatriptan for injection). A brief list of Zogenix achievements are below:• Acquired and completed development of the DosePro single use, needle free injection technology.
• In licensed a single entity oral Hydrocodone product for pain that utilizes Elan’s SODAS controlled release drug delivery technology – Phase 3 initiation in Q1 2010.
• Licensed SUMAVEL DosePro to Desitin Pharma for commercialization in Europe. Desitin completed the pivotal registration study for SUMAVEL DosePro and filed for approval in Europe in October 09.
• July 09, the U.S. FDA approved the NDA for SUMAVEL DosePro
• August 09, signed U.S. co-promotion agreement with Astellas Pharma U.S.
• January 2010 U.S. launched SUMAVEL DosePro with Zogenix Neurology Sales force and Astellas Pharma Primary Care Physician Sales force.
The winners will be announced at an awards ceremony on Tuesday, January 26 at the Drug Delivery Partnerships International Conference.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment